30-Day and 1-Year Outcomes With HYDRA Self-Expanding Transcatheter Aortic Valve

An Update on New Generation Transcatheter Aortic Valves and Delivery Systems

“…Furthermore, the wide cells in the stent frame favor coronary access, and at the same time, allow for a low profile delivery catheter, which may partly mitigate major vascular complications and strokes. More evidence on the Hydra THV performance came from the Hydra CE pre-market prospective study: 157 patients were enrolled in European and Asia-Pacific centers reporting a 30-day death rate of 7.0% (of whom 5.7% of cardiac causes), 30-day moderate/severe PVL rate of 6.3%, and 6.9% at 1-year while PPM rate was 11.7% at 30-days and 12.4% at 1-year [20].…”

“…The lower closed cells of Myval THV are covered externally with a polyethylene terephthalate sealing cuff made to form an external buffing zone that reduces the risk of PVL [51,52]. Myval is available in many sizes: conventional (20,23,26, and 29 mm), medium (21.5, 24.5, and 27.5 mm), and extra-large (30.5 and 32 mm). This THV is crimped over the balloon (Mammooth) outside the patient.…”